15353-j-veluchamy

4 NK cell ADCC enhances treatment efficacy in colorectal cancer | 113 28. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(9):5199-204. 29. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008;32(3):633- 41. 30. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti- Lymphoma Therapy. The Journal of Immunology. 2008;180(9):6392-401. 31. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immunity. 2009;15(2):91-100. 32. van den Ingh HF, Ruiter DJ, Griffioen G, van Muijen GN, Ferrone S. HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. British Journal of Cancer. 1987;55(2):125-30. 33. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, et al. Down- regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Laboratory investigation; a journal of technical methods and pathology. 2002;82(12):1725-33. 34. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcγRIIa- FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan. Journal of Clinical Oncology. 2009;27(7):1122-9. 35. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, et al. Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β2-Integrin- Mediated Interaction. Neoplasia. 2009;11(7):662-71. 36. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS. 2009;117(12):870-9. 37. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863-75. 38. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011;3(12):1445-59. 39. Koehl U, Brehm C, Huenecke S, Zimmermann S-Y, Kloess S, Bremm M, et al. Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol. Frontiers in Oncology. 2013;3:118. 40. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, et al. High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE. 2010;5(2):e9221.